B+
Bull case
20%
Probability
Target price
$18.00
+77.0% vs current
DSGN
Design TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$14.00
+37.7% vs current
B-
Bear case
20%
Probability
Target price
$7.00
-31.2% vs current
AI sentiment snapshot
Latest data as of 2026-03-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+81.1
Score
AI commentary
Market tone is cautiously constructive following the company's Q4/FY2025 release and 8-K; coverage shows a buy-leaning analyst consensus but with dispersion in targets [#IR-undated][#8-K-2026-03-09]. Investor focus is on program milestones and cash runway; sentiment will swing around upcoming operational updates [#10-K-2026-03-09].
RankAlpha Sentiment AI - 2026-03-15
Open full AI memoEvidence flagged
small-cap biotech buy thesis remains too speculative for a standard-conviction report
Impact
degraded
Confidence
-
AI events
2026-06-13eventQuarterly / operational results posting (follow-up to 8-K release)High impact
8-K filed 2026-03-09 reports results of operations and financial condition; next quarterly disclosures and related management commentary (cost, cash runway, program pacing) are an event risk to watch for near-term funding/runway implications [#8-K-2026-03-09][#10-Q-2025-11-05].
2027-03-15catalystClinical progress / program updates for GeneTAC portfolioHigh impact
Company disclosed full-year 2025 results and recent business updates and said it advanced multiple GeneTAC programs; market should expect program-specific development updates and enrollment/progression milestones through 2026 that drive re-rating [#IR-undated][#10-K-2026-03-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-03-15 • Updated nightlySource: Internal modelMethodology